Literature DB >> 9231743

Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus.

C Moret1, M Briley.   

Abstract

Milnacipran, a dual noradrenaline (NA) and serotonin (5-hydroxytryptamine, 5-HT) uptake inhibitor, increased extracellular levels of NA and 5-HT in hypothalamus of freely moving guinea pigs as measured by microdialysis. The basal levels of both monoamines, which were tetrodotoxin sensitive, were increased in a dose-dependent manner and to a similar extent after the intraperitoneal administration of milnacipran (10 and 40 mg/ kg i.p.). Levels of the NA metabolite 4-hydroxy-3-methoxyphenylglycol (MHPG) were decreased by milnacipran at 10 and 40 mg/kg i.p., whereas those of the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA) showed no effect. Subcutaneous injection of 5-HT1A and beta-adrenergic receptor antagonist (-)-pindolol alone, at 10 mg/kg, had no effect on the extracellular levels of NA or 5-HT. The concomitant administration of (-)-pindolol (10 mg/kg s.c.) with milnacipran (10 mg/kg i.p.) increased severalfold the effect of milnacipran on the extracellular levels of NA and 5-HT. These results indicate that milnacipran, by blocking the uptake of NA and 5-HT, increases virtually equipotently the extracellular levels of NA and 5-HT, confirming previous in vitro studies. In addition, the antagonism of 5-HT1A autoreceptors by (-)-pindolol potentiates the action of milnacipran on both NA and 5-HT systems, without modifying the ratio of these activities.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9231743     DOI: 10.1046/j.1471-4159.1997.69020815.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Effects of repeated milnacipran administration on brain serotonergic and noradrenergic functions in healthy volunteers.

Authors:  Atsushi Soya; Takeshi Terao; Mami Nakajima; Hideki Kojima; Tatsuya Okamoto; Yoshiaki Inoue; Miki Iwakawa; Koji Shinkai; Reiji Yoshimura; Yoichi Ueta; Jun Nakamura
Journal:  Psychopharmacology (Berl)       Date:  2006-07-08       Impact factor: 4.530

Review 2.  Prefrontal cortex executive processes affected by stress in health and disease.

Authors:  Milena Girotti; Samantha M Adler; Sarah E Bulin; Elizabeth A Fucich; Denisse Paredes; David A Morilak
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-07-06       Impact factor: 5.067

3.  Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia.

Authors:  Robert H Palmer; Antonia Periclou; Pradeep Banerjee
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

4.  Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.

Authors:  Christian Puozzo; Simone Lens; Christian Reh; Karl Michaelis; Dominique Rosillon; Xavier Deroubaix; Dominique Deprez
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  New and emerging therapeutic agents for the treatment of fibromyalgia: an update.

Authors:  Jill M Recla
Journal:  J Pain Res       Date:  2010-07-22       Impact factor: 3.133

6.  The noradrenergic symptom cluster: clinical expression and neuropharmacology.

Authors:  Pierre Blier; Mike Briley
Journal:  Neuropsychiatr Dis Treat       Date:  2011-06-03       Impact factor: 2.570

7.  Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan.

Authors:  Teruhiko Higuchi; Mike Briley
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

8.  Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?

Authors:  Fumihiko Okada
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.